Lords Mark Industries Limited has acquired a 30% equity stake in Aivita Private Limited for a cash consideration of ₹3,00,000, marking a strategic expansion into the robotic surgery sector. The acquisition, completed on July 3, 2026, involves the purchase of 30,000 equity shares of ₹10 each. This move positions Aivita as an associate company of Lords Mark Industries Limited, aligning with the acquirer's long-term vision to bolster India's healthcare infrastructure through advanced medical technologies and indigenous innovation.

Aivita Private Limited is a healthcare technology company incorporated on April 23, 2026, under the Companies Act, 2013. The entity focuses on building an execution and intelligence layer for robotic surgery in India. As a recently incorporated entity, Aivita holds an Authorised Share Capital of ₹25,00,000 and a Paid-up Share Capital of ₹10,00,000. Audited financial statements and turnover details are not yet available due to its recent establishment.

The transaction does not constitute a related party transaction, and no interests are held by the promoter or promoter group of Lords Mark Industries Limited in Aivita. The acquisition was executed for cash, and no specific governmental or regulatory approvals were required beyond standard statutory compliances. The investment is intended to confer significant influence over Aivita, facilitating the deployment of robotic surgical platforms and enhancing surgeon training programs.

Mr. Sachidanand Upadhyay, Managing Director of Lords Mark Industries Limited, emphasized that the investment is a commitment to the future of Indian healthcare. He stated that the strategic shareholding aims to make advanced robotic surgery more accessible, strengthen clinical capabilities, and foster an ecosystem where technology improves patient outcomes. The acquisition complements Lords Mark's existing healthcare portfolio, which includes diagnostics, medical devices, AI-enabled solutions, and indigenous manufacturing.

Key Details of the Acquisition

Strategic Objectives

The acquisition is designed to integrate Aivita's technological capabilities with Lords Mark's healthcare portfolio. The companies aim to create a hardware-agnostic robotic surgery ecosystem that connects technology, hospitals, clinicians, and healthcare data. This initiative seeks to improve the utilization of advanced medical infrastructure and promote technology-enabled collaboration across the country's healthcare sector.

Lords Mark Industries Limited has commenced operations at its new state-of-the-art In Vitro Diagnostics (IVD) manufacturing facility in Vasai (East), Maharashtra. The unit, measuring approximately 14,000 sq. ft., became operational two months ahead of its originally scheduled August 2026 timeline. This development increases the company's total operational manufacturing footprint from 20,000 sq. ft. to 34,000 sq. ft., significantly boosting its production capabilities in the diagnostics sector.

Manufacturing Capacity and Product Portfolio

The new facility is designed to manufacture a portfolio of 56 ELISA test kits alongside a new range of rapid diagnostic test kits. The enhanced capacity is intended to improve operational efficiency and support increasing market demand. The company has outlined that this expansion will strengthen its position in the diagnostics sector by catering to broader healthcare needs.

The following table summarises the key details of the new facility:

Research and Development Initiatives

The Research & Development division within the new facility has been dedicated to the memory of Late Shri Ratan Tata. This division will focus on indigenous molecular biology research and genetic science initiatives aimed at strengthening domestic scientific capabilities. The company's management emphasized that this move aligns with its commitment to building world-class healthcare infrastructure within India.

Future Expansion Plans

As part of its long-term growth strategy, Lords Mark Industries Limited has planned the establishment of a third facility at Vasai, Maharashtra. This proposed unit will be dedicated to research for early cancer detection and will be named in honour of the Late Dr. A.P.J. Abdul Kalam. The company expects this facility to commence operations from January 2029. Additionally, the firm has outlined a vision to establish one of the world's largest medical device manufacturing facilities in India, focusing on AI-enabled and imaging-based diagnostic devices.

Mr. Sachidanand Upadhyay, Managing Director of Lords Mark Industries Limited, stated that the milestone is guided by the conviction that world-class healthcare must be built in India, for India and the world. He highlighted the company's focus on indigenous science, earlier cancer detection, and accessible diagnostic devices.